

Dr Kerr

**To get ready, please
visit the URL below**

doctorkerr.com.au/interact





Glaucoma Management: When, Which, and How



Dr. Nathan Kerr

Saving sight. Changing lives.



Welcome

Dr. Nathan Kerr

Glaucoma and Cataract Surgeon

doctorkerr.com.au/interact

About me



**THE UNIVERSITY
OF AUCKLAND**
NEW ZEALAND




the royal victorian
**eye and ear
hospital**

Moorfields
Eye Hospital **NHS**
NHS Foundation Trust



CENTRE FOR
**Eye Research
Australia**



Learning objectives

01


Identify the salient principles in the diagnosis and management of glaucoma

02

Discuss the main factors in determining when to commence the treatment of a case of glaucoma

03

Consider the treatment options and be able to customise an individual regime for each patient



“A group of progressive optic neuropathies characterised by degeneration of retinal ganglion cells and retinal nerve fibre layer resulting in changes in the optic nerve head”

Glaucoma



Goals

01

Individualise care

02

Preserve visual function

03

Promote quality of life

A close-up photograph of a human eye, showing the iris, pupil, and eyelashes. A dark, circular overlay is positioned over the center of the eye, partially covering the pupil and iris. The text "Glaucoma in Australia" is overlaid in white, centered horizontally across the eye.

Glaucoma in Australia

Glaucoma in Australia

1:8 people
Over 80 years

600,000
Australians

#1 cause
Irreversible
blindness



Glaucoma in Australia

tvst

DOI: 10.1167/tvst.4.2.1

Perspective

Why Do People (Still) Go Blind from Glaucoma?

Remo Susanna Jr.¹, Carlos Gustavo De Moraes², George A. Cioffi², and Robert Ritch³

¹ Department of Ophthalmology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil

² Department of Ophthalmology, Columbia University Medical Center, New York, NY, USA


³ Einhorn Clinical Research Center, New York Eye & Ear Infirmary of Mount Sinai, New York, NY, USA

Susanna R, De Moraes CG, Cioffi GA, Ritch R. Why do people (still) go blind from glaucoma? Translational Vision Science & Technology. 2015 Mar;4(2):1-12

Glaucoma in Australia

- 01 Glaucoma is (still) undiagnosed
- 02 Glaucoma is (still) improperly treated
- 03 (Still) lack of adherence


Susanna R, De Moraes CG, Cioffi GA, Ritch R. Why do people (still) go blind from glaucoma? Translational Vision Science & Technology. 2015 Mar;4(2):1-12



Recent developments in
glaucoma have required
revisiting treatment algorithms
and integrating traditional and
novel approaches to ensure
optimal outcomes


Interactive seminar

5 clinical cases



Interactive seminar


Ask a question



Interactive seminar

Ask a question

Vote




Interactive seminar


Ask a question

Vote


Download slides or a
summary



Interactive seminar



Glaucoma Management: When, Which, and How

 **Dr. Nathan Kerr**

Saving sight. Changing lives.

Dr Kerr

Glaucoma Management – When, Which, and How

Presenter: Dr Nathan Kerr
Australian College of Optometry Seminar Series, Tuesday 18 June 2019

Learning Objectives

1. Identify the salient principles in the diagnosis and management of glaucoma
2. Discuss the main factors in determining when to commence the treatment of a case of glaucoma
3. Consider the treatment options and be able to customise an individual regime for each patient

Glaucoma

- A group of progressive optic neuropathies characterised by degeneration of retinal ganglion cells resulting in changes in the optic nerve head
- Still a leading cause of irreversible vision loss in Australia
- The major proven treatment is to lower intraocular pressure (IOP)
- The goal of treatment is to maintain the patient's visual function and related quality of life
- Therapy should be individualised to the patient's needs and preferences
- Recent developments in the therapeutic field have led to changes in treatment paradigms

Classification

- Glaucoma is classified into two major subtypes – open-angle and closed-angle
- Both open-angle and closed-angle glaucoma can be either primary or secondary

Primary glaucoma is where there is no identifiable cause

- Secondary glaucoma refers to any form of glaucoma where there is an identifiable cause of raised IOP

Open-angle

- Primary open-angle glaucoma is the most common form
- Normal-tension glaucoma occurs with IOP consistently 21 mmHg or less and show field defects closer to fixation, more localised retinal nerve fibre layer defects, and increased tendency for disc haemorrhages
- Secondary open-angle glaucoma is most commonly pseudoexfoliative and is associated with higher IOP and greater risk of blindness

Closed-angle

- Closed-angle can be classified as primary angle-closure suspect (PACS), primary angle-closure (PAC), or primary angle-closure glaucoma (PACG)

	TM < 180°	↑ IOP or PAS	GON
PACS	+	-	-
PAC	+	+	-
PACG	+	+	+

Staging

- Glaucoma can be staged according to severity
- Early: Mild defect not within 10° of fixation (MD better than -6 dB)

Dr Nathan Kerr MBChB, MD, FRANZCO
Glaucoma and Cataract Surgeon | Eye Surgery Associates


Phone: 1300 GLAUCOMA Email: nathan@doctorkerr.com.au Web: doctorkerr.com.au


10:09 Not Secure — doctorkerr.com.au

Dr Kerr

[Ask a question](#)


Powered by Mentimeter [Terms](#)

 Slides
Download the slides
[Download](#)

 Seminar Notes
Download a summary
[Download](#)

TIP Please [enable cookies](#) to access the polls.

ABOUT DR NATHAN KERR
LOCATIONS
REFER A PATIENT
PRIVACY

[in](#) 

— Case 1

Identifying patients
at risk of glaucoma



Case 1

Demographics

Female, 56 years old

History

Disc cupping and RNFL changes

Past ocular history

Myopia. No raised IOP.

Past medical history

Osteoarthritis

Family history

Nil

Case 1

What would you like to ask about her past medical history?



Slide is not active

Activate



0



0

Case 1

Right eye

6/4.8

-0.25/-0.75x80

13

529

Deep & quiet

Grade 4

No cataract

0.8

Examination

Visual acuity

Refraction

IOP

CCT

AC

Gonio

Lens

Fundus

Left eye

6/4.8

0.00/-1.00x90

13


531

Deep & quiet



Grade 4

No cataract






0.8




Disc Center(0.00,-0.09)mm
 Extracted Horizontal Tomogram





RNFL Circular Tomogram





	OD μm	OS μm
Average GCL + IPL Thickness	81	70
Minimum GCL + IPL Thickness	82	44



Disc Center(0.00,0.03)mm
 Extracted Horizontal Tomogram



RNFL Circular Tomogram




Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 3/15 xx
 False POS Errors: 2 %
 False NEG Errors: 11 %
 Test Duration: 05:26

Stimulus: Ill, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter:
 Visual Acuity:
 RX: +2.50 DS DC X

Date: 17-06-2019
 Time: 2:24 PM
 Age: 56

Fovea: OFF



-23	-3	-3	-3
-3	0	-2	-2
-2	-3	-3	-2
-4	-3	-3	-2
-1	-8	-3	-12
-5	-4	-3	-3
-3	-2	-4	-3
0	-3	-4	-3

Total Deviation

-22	-2	-3	-3
-2	0	-1	-2
-2	-2	-2	-1
-3	-2	-2	-1
0	-7	-2	-11
-4	-3	-2	-2
-2	-2	-3	-2
0	-2	-3	-3

Pattern Deviation

*** Low Test Reliability ***

GHT
 Outside Normal Limits

VFI 96%

MD -2.85 dB P < 2%

PSD 3.01 dB P < 2%

∴ < 5%
 ⦿ < 2%
 ⦿ < 1%
 ■ < 0.5%

Eye Surgery Associates
 Level 2, 232 Victoria Pde.
 East Melbourne Vic 3002
 Ph. 03 9416 0695


Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 1/13
 False POS Errors: 3 %
 False NEG Errors: 4 %
 Test Duration: 04:39

Stimulus: Ill, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter:
 Visual Acuity:
 RX: +2.50 DS DC X

Date: 17-06-2019
 Time: 2:18 PM
 Age: 56

Fovea: OFF



-1	-1	-1	2
1	1	1	-1
3	0	0	0
2	-1	3	0
1	-1	1	3
-1	-1	0	-1
0	1	1	-1
2	1	0	0

Total Deviation

-3	-3	-4	-1
-2	-1	-1	-3
1	-2	-2	-2
0	-3	1	-2
-1	-3	-2	1
-3	-3	-2	-3
-3	-1	-1	-3
0	-1	-3	-2

Pattern Deviation

GHT
 Within Normal Limits

VFI 100%


MD +0.57 dB

PSD 1.46 dB

∴ < 5%
 ⦿ < 2%
 ⦿ < 1%
 ■ < 0.5%

Eye Surgery Associates
 Level 2, 232 Victoria Pde.
 East Melbourne Vic 3002
 Ph. 03 9416 0695

Which of the following are risk factors for glaucoma?



Slide is not active




0



0

Major risk factors for glaucoma



Identifying those at risk of glaucoma

Recommendation

- Identify and assess glaucoma patients and suspects (those at high risk of disease)


Good practice

- Perform regular eye health checks on all first-degree relatives of glaucoma patients



Good practice

- Survey for glaucoma in patients over 50 especially with myopia, hypertension, diabetes, peripheral vasospasm, steroid use, or eye injury

Assessment and follow-up



6 months prior...



— Case 2

Ocular hypertension



Case 2

Demographics

Female, 54 years old

History

Asymptomatic

Past ocular history

Nil

Past medical history

Depression

Family history

Glaucoma - mother and grandmother

Case 2

Right eye

6/6

Plano

23

575

Deep & quiet

Grade 4

No cataract

0.5

Examination

Visual acuity

Refraction

IOP

CCT

AC

Gonio

Lens

Fundus

Left eye

6/6

Plano

25


585

Deep & quiet









Grade 4

No cataract




0.5



Disc Center(0.00,0.06)mm
Extracted Horizontal Tomogram





Disc Center(0.12,-0.15)mm
Extracted Horizontal Tomogram



Ganglion Cell OU Analysis: Macular Cube 512x128

OD ● OS




Fixation Monitor: Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/15
 False POS Errors: 0 %
 False NEG Errors: 0 %
 Test Duration: 05:56

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter:
 Visual Acuity:
 RX: +0.50 DS DC X


Date: 29-05-2017
 Time: 10:21 AM
 Age: 52

Fovea: OFF




-5	-3	0	-1				
-5	-2	-4	-1	-2	-1		
-3	-3	-3	-2	-2	-2	-2	
0	-1	1	1	0	-1	-2	0
-2	0	0	2	1	0	-2	1
2	1	1	0	1	0	-2	0
-1	0	-1	-1	0	0		
1	0	-2	0				

Total Deviation



-6	-4	-1	-2				
-5	-3	-5	-2	-3	-1		
-4	-4	-3	-2	-3	-3	-3	
-1	-2	0	0	-1	-2	-3	-1
-3	-1	-1	1	0	-1	-3	0
1	0	1	-1	0	-1	-3	0
-2	-1	-2	-2	-1	-1		
0	-1	-3	-1				

Pattern Deviation



GHT
 Within Normal Limits
 VFI 99%
 MD -0.71 dB
 PSD 1.59 dB

Eye Surgery Associates
 East Melbourne

⋯ < 5%
 ⋯ < 2%
 ⋯ < 1%
 ■ < 0.5%


Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/14
 False POS Errors: 0 %
 False NEG Errors: 0 %
 Test Duration: 05:37

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 6.1 mm
 Visual Acuity:
 RX: +2.25 DS -1.25 DC X 40


Date: 29-05-2017
 Time: 10:14 AM
 Age: 52

Fovea: OFF




-1	0	-5	-3				
-3	-2	-1	0	2	1		
2	-3	-2	-1	-1	1	0	-1
0	0	-1	0	-1	0	0	-2
0	0	0	-1	0	2	1	-1
0	-1	-1	-1	0	-3	-1	2
1	0	-3	1	1	0		
1	0	-1	-1				

Total Deviation



-2	-1	-6	-4				
-4	-3	-2	-1	1	0		
1	-4	-3	-2	-2	0	-1	-1
-1	0	-2	-1	-2	-1	0	-3
-1	-1	0	-2	0	1	0	-1
-1	-2	-1	-2	-1	-4	-2	1
0	-1	-4	0	0	-1		
0	-1	-1	-2				

Pattern Deviation



GHT
 Within Normal Limits
 VFI 99%
 MD -0.47 dB
 PSD 1.43 dB

Eye Surgery Associates
 East Melbourne

⋯ < 5%
 ⋯ < 2%
 ⋯ < 1%
 ■ < 0.5%

How would you manage this patient?



Slide is not active




0



0

What factors influenced your decision?



Slide is not active



Risk of conversion to glaucoma

Age

- HR 1.2 per decade

Higher IOP

- HR 1.1 per mmHg

Large CDR

- HR 1.2 per 0.1

Greater PSD

- HR 1.3 per 0.2 dB

Thinner CCT

- CCT < 555 microns associated with 3x risk of conversion

Managing ocular hypertension

Recommendation

- Assess risk of conversion from ocular hypertension to glaucoma


Good practice

- Patients at low risk of conversion should be considered for monitoring

Good practice

- Patients at high risk of conversion should be considered for treatment

Managing ocular hypertension



— Case 3

Pre-perimetric
primary open-angle
glaucoma



Case 3

Demographics

Male, 37 years old

History

Asymptomatic

Past ocular history

Ocular hypertension diagnosed 2015, IOPs 25;
high myopia

Past medical history

Nil

Family history

Glaucoma – maternal and paternal grandparents

Case 3

Right eye

6/6

-7.75

22

483

Deep & quiet

Grade 4

No cataract

0.7

Examination

Visual acuity

Refraction

IOP

CCT

AC

Gonio

Lens

Fundus

Left eye

6/6

-8.25

24

485


Deep & quiet

Grade 4


No cataract

0.7


RNFL Deviation Map




Disc Center(-0.06,0.00)mm
Extracted Horizontal Tomogram




Extracted Vertical Tomogram




Neuro-retinal Rim Thickness




RNFL Thickness





RNFL Deviation Map



Disc Center(0.06,0.09)mm
Extracted Horizontal Tomogram





Extracted Vertical Tomogram



Ganglion Cell OU Analysis: Macular Cube 512x128

OD ● | ● OS




Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/15
 False POS Errors: 0 %
 False NEG Errors: 2 %
 Test Duration: 04:57

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 5.7 mm
 Visual Acuity:
 RX: -5.50 DS DC X

Date: 13-11-2017
 Time: 9:01 AM
 Age: 35

Fovea: OFF



-3	-3	-5	-3				
-6	-4	-4	-5	-2	-4		
-4	-4	-2	-3	-4	-3	-2	-4
-3	-1	-2	-1	-1	-2	-1	-3
-2	-1	0	-2	-3	-2	0	-4
-3	0	-1	-2	-1	0	-3	-3
0	0	-4	-2	0	-2		
-1	-1	-2	-6				

Total Deviation

-2	-3	-4	-2				
-6	-3	-3	-4	-2	-3		
-3	-4	-2	-3	-3	-2	-1	-4
-3	0	-1	0	0	-1	-1	-2
-1	0	1	-1	-2	-1	0	-4
-2	0	-1	-1	0	1	-3	-2
0	0	-4	-1	1	-2		
0	0	-2	-6				

Pattern Deviation

GHT
 Within Normal Limits

VFI 99%

MD -2.17 dB P < 5%

PSD 1.64 dB

:: < 5%
 ☼ < 2%
 ☼☼ < 1%
 ■ < 0.5%

Eye Surgery Associates
 East Melbourne


Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/14
 False POS Errors: 0 %
 False NEG Errors: 4 %
 Test Duration: 05:07

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 8.6 mm
 Visual Acuity:
 RX: -4.50 DS -1.75 DC X 3

Date: 13-11-2017
 Time: 8:53 AM
 Age: 35

Fovea: OFF



-3	-5	-7	-4				
-2	-3	-4	-6	-4	-2		
-5	-2	-2	-3	-4	-5	-3	-4
-4	-5	-2	-3	-1	-3	-3	-4
-7	-1	-2	-2	-1	-1	-1	0
0	-1	1	-3	0	-3	0	-2
-3	1	-4	-1	0	0		
2	-1	-1	-2				

Total Deviation

-2	-5	-7	-4				
-2	-3	-4	-6	-4	-2		
-5	-2	-2	-3	-4	-5	-3	-3
-4	-5	-2	-2	-1	-3	-3	-4
-7	0	-2	-2	-1	-1	-1	0
0	-1	1	-2	0	-2	0	-1
-2	1	-4	-1	0	0		
2	-1	-1	-2				

Pattern Deviation

GHT
 Within Normal Limits

VFI 98%

MD -2.19 dB P < 5%

PSD 1.85 dB P < 10%

:: < 5%
 ☼ < 2%
 ☼☼ < 1%
 ■ < 0.5%

Eye Surgery Associates
 East Melbourne

What target pressure would you set?



Slide is not active [Activate](#)




0




0

General principals of glaucoma treatment




Considerations for setting target IOP




The treatment target is a compromise between reducing the risk of symptomatic vision loss and the consequences of therapy. Patient preferences should be taken into account.

Setting the target IOP



Revaluating the target IOP




How would you manage this patient?



 Slide is not active


 0  0

Considerations on treatment options



A first choice treatment is considered a drug that the treating physician prefers to use as initial IOP lowering therapy as opposed to the first line treatment, which is one that has been approved by an official controlling body, like EMEA, FDA or National Agencies.

Evidence



LiGHT Trial

Gazzard, Gus, et al. "Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial." *The Lancet* (2019)

— Case 4

Primary angle closure
suspect



Case 4

Demographics

Female, 54 years old

History

Asymptomatic

Past ocular history

Hyperopia

Past medical history

Type 2 diabetes mellitus

Family history

Nil

Case 4

Right eye

6/4.8

+3.75

17

591

Shallow & quiet

Grade 1, no PAS

No cataract

0.2

Examination

Visual acuity

Refraction

IOP

CCT

AC

Gonio

Lens

Fundus

Left eye

6/4.8

+3.75

16

596


Shallow & quiet

Grade 1, no PAS





No cataract

0.2



ONH and RNFL OU Analysis: Optic Disc Cube 200x200 OD ● ● OS




	OD	OS
Average RNFL Thickness	115 μm	113 μm
RNFL Symmetry	84%	
Rim Area	1.79 mm^2	1.95 mm^2
Disc Area	1.90 mm^2	2.03 mm^2
Average C/D Ratio	0.24	0.20
Vertical C/D Ratio	0.14	0.17
Cup Volume	0.009 mm^3	0.001 mm^3





Disc Center(0.03,-0.15)mm
Extracted Horizontal Tomogram




Disc Center(0.30,-0.21)mm
Extracted Horizontal Tomogram



Extracted Vertical Tomogram





Extracted Vertical Tomogram



Ganglion Cell OU Analysis: Macular Cube 512x128

OD ● OS




Fixation Monitor: Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/14
 False POS Errors: 0 %
 False NEG Errors: 0 %
 Test Duration: 04:27

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter:
 Visual Acuity:
 RX: +5.75 DS DC X

Date: 20-05-2019
 Time: 4:51 PM
 Age: 54

Fovea: OFF



0	2	0	0				
2	2	0	-1	1	0		
0	2	1	2	2	0	0	-1
-1	0	1	2	0	1	-1	-4
2	0	2	1	1	1	-2	-5
-2	1	1	0	1	0	-1	-2
1	1	-1	-1	0	-1		
1	2	0	-1				

Total Deviation

-2	0	-2	-2				
0	0	-2	-3	-1	-1		
-1	0	-1	1	0	-2	-2	-3
-3	-2	-1	0	-2	-1	-2	-5
0	-1	0	-1	0	0	-4	-6
-3	-1	0	-2	0	-1	-2	-3
-1	0	-3	-2	-1	-2		
0	0	-2	-2				

Pattern Deviation

GHT
 Within Normal Limits
 VFI 100%
 MD +0.35 dB
 PSD 1.29 dB

Eye Surgery Associates
 East Melbourne

∴ < 5%
 ⦿ < 2%
 ⦿ < 1%
 ■ < 0.5%


Fixation Monitor: Gaze/Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/13
 False POS Errors: 0 %
 False NEG Errors: 0 %
 Test Duration: 04:15

Stimulus: III, White
 Background: 31.5 ASB
 Strategy: SITA-Standard

Pupil Diameter: 5.3 mm
 Visual Acuity:
 RX: +6.25 DS -1.25 DC X 13

Date: 20-05-2019
 Time: 4:45 PM
 Age: 54

Fovea: OFF



1	-2	1	1				
1	1	0	0	2	2		
-1	-2	0	0	0	1	2	0
-3	0	0	-1	1	1	3	-1
-3	0	1	0	2	1	0	1
0	-1	1	2	0	-2	1	0
-1	0	0	0	-2	-1		
1	0	-2	0				

Total Deviation

-1	-3	-1	0				
0	0	-2	-1	0	0		
-2	-3	-2	-2	-1	-1	0	-1
-4	-1	-1	-2	0	0	1	-2
-4	-1	0	-1	1	0	-2	-1
-2	-2	0	0	-1	-3	-1	-1
-3	-1	-1	-2	-3	-2		
-1	-1	-4	-1				

Pattern Deviation

GHT
 Within Normal Limits
 VFI 100%
 MD +0.24 dB
 PSD 1.23 dB

Eye Surgery Associates
 East Melbourne

∴ < 5%
 ⦿ < 2%
 ⦿ < 1%
 ■ < 0.5%

What is the diagnosis?







 Slide is not active

 0  0

How would you manage this patient?

0	0	0	0
Observe	Refer for laser iridotomy	Refer for laser iridoplasty	Refer for lens extraction

  Slide is not active

 0  0

Evidence

ZAP Trial

Study

- Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial

Study design

- Randomized controlled trial

Participants

- Bilateral primary angle closure suspects aged 50-70 years

Intervention and control

- Laser peripheral iridotomy in one eye selected at random

Results

- Laser peripheral iridotomy reduced the risk of angle-closure events, however the incidence of angle-closure was very low

He, Mingguang, et al. "Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial." *The Lancet* (2019).

— Case 5

Primary angle closure
glaucoma



Case 5

Demographics

Male, 63 years old

History

Concerned about surgery in better eye

Past ocular history

Bilateral primary angle closure glaucoma, complicated right trabeculectomy 2011; maximum medical therapy left eye

Past medical history

Asthma

Family history

Glaucoma - brother

Case 5

Right eye

6/15

Plano

14

498

Shallow & quiet

Grade 1, PAS

No cataract

0.85

Examination

Visual acuity

Refraction

IOP

CCT

AC

Gonio

Lens

Fundus

Left eye

6/6

+1.5

25


498

Shallow & quiet



Grade 1, PAS

No cataract


0.75








	OD	OS
Average RNFL Thickness	51 μm	60 μm
RNFL Symmetry	49%	
Rim Area	0.40 mm^2	0.60 mm^2
Disc Area	1.76 mm^2	1.80 mm^2
Average C/D Ratio	0.88	0.82
Vertical C/D Ratio	0.86	0.75
Cup Volume	0.867 mm^3	0.565 mm^3




Disc Center(0.00,0.18)mm
Extracted Horizontal Tomogram




Extracted Vertical Tomogram



Disc Center(-0.03,-0.27)mm
Extracted Horizontal Tomogram




Extracted Vertical Tomogram



Ganglion Cell OU Analysis: Macular Cube 512x128


OD ● | ● OS

OD Thickness Map




Fovea: 251, 64

OS Thickness Map




Fovea: 258, 65


OD Deviation Map




OD Sectors




OS Sectors



OS Deviation Map



Diversified:
Distribution
of Normals





	OD μm	OS μm
Average GCL + IPL Thickness	49	56
Minimum GCL + IPL Thickness	44	52

OS Single Field Analysis Central 24-2 Threshold Test

Fixation Monitor: Blind Spot
 Fixation Target: Central
 Fixation Losses: 0/12
 False POS Errors: 3%
 False NEG Errors: 0%
 Test Duration: 05:03
 Fovea: Off

Stimulus: III, White
 Background: 31.5 asb
 Strategy: SITA-Standard
 Pupil Diameter:
 Visual Acuity:
 Rx: +4.75 DS

Date: Feb 22, 2018
 Time: 4:32 PM
 Age: 62



GHT: Outside Normal Limits

VFI: 96%

MD: -1.66 dB

PSD: 3.52 dB P < 1%



:: P < 5%
 ☼ P < 2%
 ☼ P < 1%
 ■ P < 0.5%

OD Single Field Analysis Central 24-2 Threshold Test

Fixation Monitor: Blind Spot
 Fixation Target: Central
 Fixation Losses: 1/15
 False POS Errors: 3%
 False NEG Errors: 6%
 Test Duration: 06:15
 Fovea: Off

Stimulus: III, White
 Background: 31.5 asb
 Strategy: SITA-Standard
 Pupil Diameter:
 Visual Acuity:
 Rx: +2.25 DS

Date: Feb 22, 2018
 Time: 4:25 PM
 Age: 62



GHT: Outside Normal Limits


VFI: 52%


MD: -17.98 dB P < 0.5%

PSD: 15.20 dB P < 0.5%

:: P < 5%
 ☼ P < 2%
 ☼ P < 1%
 ■ P < 0.5%


What surgery would you discuss with the patient?





Dr Nathan Kerr

Evidence



EAGLE Trial

Azuara-Blanco, Augusto, et al. "Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial." *The Lancet* 388.10052 (2016): 1389-1397.